Table 1. Demographic data for CF patients.
Patient | Genetics | Age | RSI score | PPI yes/no | Gastric Juice pH | FEV1 (% pred) | BMI | IV days/year | Long-term antibiotic |
---|---|---|---|---|---|---|---|---|---|
CF-1 | F508del/F508del | 26 | 17 | Yes | 6 | 2.0 L (52%) | 19.9 | 22 | Azith Inh Coli Inh Tob |
CF-2 | F508del/F508del | 27 | 20 | Yes | 2 | 1.7 L (42%) | 23.2 | 70 | Azith Fluclox Inh coli |
CF-3 | F508del/F508del | 20 | 25 | Ranitidine | 3 | 0.8 L (26%) | 19.5 | 28 | Azith Fluclox Inh Coli |
CF-4 | F508del/F508del | 24 | 36 | Yes | 6 | 0.76 L (28%) | 19 | 154 | Azith Inh Coli |
CF-5 | F508del/F508del | 31 | 16 | Yes | 6 | 0.5 L (12%) | 19.1 | 70 | Azith Inh Coli |
CF-6 | F508del/R117H | 22 | 16 | Yes | 3 | 2.7 L (66%) | 16.4 | 14 | Fluclox |
CF-7 | I507del/Arg560Lys | 18 | 13 | Yes | 2 | 3.5 L (88%) | 19.4 | 37 | Fluclox Inh Coli Inh Tob |
CF-8 | F508del/R117H | 30 | 14 | Yes | 6 | 1.55 L (46%) | 17.8 | 56 | Fluclox Inh Coli |
CF-9 | F508del/F508del | 25 | 17 | Yes | 2 | 1.7 L (38%) | 15.9 | 98 | Azith Fluclox Inh Tob |
CF-10 | F508del/G542X | 32 | NA | No | 2 | 1.15 L (36%) | 19.4 | 112 | Azith Inh Coli |
CF-11 | F508del/F508del | 30 | 19 | Yes | 6 | 1.2 L (29%) | 19.8 | 115 | Azith Fluclox Inh Coli |
CF-1 | F508del/G542X | 24 | 15 | Yes | 2 | 1.65 (36%) | 15.24 | 197 | Azith Inh Coli Inh Tob |
CF-13 | F508del/rg851Ter | 23 | 22 | Yes | 6 | 2.3 (59%) | 20.2 | 56 | Azith |
CF-14 | F508del/F508del | 25 | 24 | Yes | 4 | 0.85 L (29%) | 17.3 | 84 | Azith Inh Colistin Fluclox |
CF-15 | F508del/Arg851Ter | 25 | 8 | Yes | 3 | 2.1 L (54%) | 20.1 | 56 | Doxycycline, Azith |
CF-16 | F508del/Ile507del | 36 | NA | Yes | 4 | 0.72 L (17%) | 21.9 | 112 | Inh Colistin |
Key: Azith = oral azithromycin long-term. Fluclox = oral flucloxacillin long-term. Inh Coli = inhaled colistin (nebulised or inhaler). Inh Tob = inhaled tobramycin (nebulised or inhaler). RSI score = Reflux symptom index score, <13 normal. NA = not available, IV days/year = Number of days per year that CF patient treated with intravenous antibiotics.